Latest posts

Improved clinical outcomes to deliver new drugs for patients faster. Getting a new drug or medical device to market is a challenging process, potential risks need to be limited and

BERLIN, Germany, April 14, 2021 – LINK Medical, the Northern European clinical research organization (CRO), is continuing the expansion of its German presence. This further strengthens their position as a

From mobile apps to digital biomarkers, transformative technologies – such as artificial intelligence, machine learning and virtual reality – are enabling the creation of unique and novel digital health innovations,

UPPSALA, Sweden, February 2, 2021 – LINK Medical, the Northern European clinical research organization (CRO), and the Swedish women’s health company Gedea Biotech announced today that it has enrolled the first

LINK Medical has today announced the acquisition of IRW Consulting AB (IRW), a Nordic CRO with more than 20 years of experience in clinical research outsourcing. With this acquisition LINK

Get your study eCRF running in only a couple of weeks Case study summary: LINK Medical is attracting repeat US customers due to our flexible, experienced staff and expertise as

The Nordic countries often come out on top in innovation league tables, and yet many regional companies struggle to gain the attention of potential global partners beyond Europe. This story

When it comes to the current COVID-19 situation, RBQM is a critical concept to master as it involves more remote work and centralized efforts, which will be essential to clinical trials

Our latest article published in Denmark by Berlignske. 5 reasons why SMEs need a team of experts for a greater chance of success. Written by: Peter Klar Biotech and Medtech

OSLO, Norway, April 01 2020 – LINK Medical Research, the Northern European clinical research organization (CRO), has today announced the opening of its new UK office at MedCity, in London’s

STOCKHOLM, Sweden, December 06, 2019 – LINK Medical, the Northern European clinical research organization (CRO), today announced that it will carry out a pivotal phase III clinical trial on behalf